Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Study of JYB1904 in Healthy Chinese Subjects
NCT05449535Phase 1Completed
- Sponsor
- Jemincare
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ozureprubart in allergic asthma and chronic spontaneous urticaria (CSU) (2 arms), sponsored by Jemincare. Primary endpoint: Adverse events (AEs) at 168 days. Started May 2022; status: completed.
02
Drugs
ozureprubart
03
Conditions
allergic asthmachronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05449535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449535.